Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
NCT05968703
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson's Disease
- Mild Cognitive Impairment
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Helen M. Bronte-Stewart
- Last updated on ClinicalTrials.gov
- May 30, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford Neuroscience Health Center · Stanford, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.